Affordable Access

A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).

Authors
  • Laack, Eckart
  • Thöm, Ina
  • Krüll, Andreas
  • Engel-Riedel, Walburga
  • Müller, Thomas
  • Meissner, Christoph
  • Dürk, Heinz
  • Fischer, Jürgen
  • Gütz, Sylvia
  • Kortsik, Cornelius
  • Elbers, Matthias
  • Schuch, Gunter
  • Andritzky, Birte
  • Görn, Michael
  • Burkholder, Iris
  • Edler, Lutz
  • Hossfeld, Dieter Kurt
  • Bokemeyer, Carsten
Type
Published Article
Journal
Lung Cancer
Publisher
Elsevier
Publication Date
Aug 01, 2007
Volume
57
Issue
2
Pages
181–186
Identifiers
PMID: 17442447
Source
Medline
License
Unknown

Abstract

The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.

Report this publication

Statistics

Seen <100 times